Bayesian Capital Management’s Royalty Pharma RPRX Stock Holding History

Bayesian Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-49,975	Closed	-$1.76M	–	459
2025 Q3	$1.76M	Buy	+49,975	New	+$1.81M	0.36%	82
2024 Q1	–	Sell	-15,252	Closed	-$428K	–	1069
2023 Q4	$428K	Buy	+15,252	New	+$419K	0.05%	417
2021 Q3	–	Sell	-19,300	Closed	-$791K	–	507
2021 Q2	$791K	Buy	+19,300	New	+$821K	0.21%	125

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bayesian Capital Management's RPRX Position: Q4 2025 in Review

Bayesian Capital Management sold out of Royalty Pharma (RPRX) in Q4 2025, closing a stake of 49,975 shares — an estimated $1.76M sold.

Bayesian Capital Management first reported a position in RPRX in Q2 2021 and held it in 3 quarters. The position peaked at $1.76M in Q3 2025. 539 funds tracked by Wall St. Rank hold RPRX as of Q4 2025.

Bayesian Capital Management reported no remaining Royalty Pharma position as of Q4 2025 after selling out during the quarter.
Bayesian Capital Management sold 49,975 Royalty Pharma shares in Q4 2025, an estimated $1.76M.
Bayesian Capital Management first reported a position in Royalty Pharma in Q2 2021 and held it in 3 quarters.
Bayesian Capital Management's Royalty Pharma position peaked at $1.76M in Q3 2025.
539 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2025.

Based on Bayesian Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.